Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In Italy, there is no national or regional registry for non-infectious chronic uveitis as per the Prime Ministerial Decree (DPCM) of March 3, 2017 (Identification of surveillance systems and registries for mortality, tumors, and other diseases). However, many clinical centers adopt data recording systems to evaluate the quality of care and to study diseases and outcomes. The Universitary Hospital Meyer Institute Research Hospital (IRCCS) is a national referral center for managing these pediatric cases of non-infectious chronic uveitis, estimated to constitute 95% of all pediatric uveitis cases
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Describe a population of paediatric patients with chronic non-infectious uveitis
Timeframe: thorugh the study and after 1 year
Describe a population of paediatric patients with chronic non-infectious uveitis
Timeframe: 6 months, 12 months, 2 years and then every year
Identify any differences between the different forms of uveitis in terms of characteristics and outcomes
Timeframe: thorugh the study and after 1 year
Identify risk factors for a more severe course
Timeframe: thorugh the study and after 1 year
Frequency achievement of response for each drug according to the definition of response
Timeframe: thorugh the study and after 1 year
Time to archieve the response after drug initiation
Timeframe: thorugh the study and after 1 year
Achievement of inactive disease on therapy according to the definition of MIWGUC
Timeframe: thorugh the study and after 1 year
Time to achieve inactive disease on therapy according to the definition of MIWGUC
Timeframe: thorugh the study and after 1 year
Presence and percentages of flares on therapy after achievement of remission on therapy
Timeframe: thorugh the study and after 1 year
Time to the first flare on therapy
Timeframe: thorugh the study and after 1 year
Time to flare after drug withdrawal
Timeframe: 6, 12 and 18 months, 2 years then every year